Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
Sep 25, 2017•7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast